Cargando…

Clinical value of selected markers of angiogenesis, inflammation, insulin resistance and obesity in type 1 endometrial cancer

BACKGROUND: It is a well-known fact show that the risk of developing endometrial cancer (type 1 EC) is strongly associated with obesity. In this study, selected markers, such as obesity, insulin resistance, angiogenesis and inflammation markers related to EC type 1 progression and patients’ survival...

Descripción completa

Detalles Bibliográficos
Autores principales: Terlikowska, Katarzyna M., Dobrzycka, Bozena, Terlikowski, Robert, Sienkiewicz, Anna, Kinalski, Maciej, Terlikowski, Slawomir J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519537/
https://www.ncbi.nlm.nih.gov/pubmed/32977765
http://dx.doi.org/10.1186/s12885-020-07415-x
_version_ 1783587591979794432
author Terlikowska, Katarzyna M.
Dobrzycka, Bozena
Terlikowski, Robert
Sienkiewicz, Anna
Kinalski, Maciej
Terlikowski, Slawomir J.
author_facet Terlikowska, Katarzyna M.
Dobrzycka, Bozena
Terlikowski, Robert
Sienkiewicz, Anna
Kinalski, Maciej
Terlikowski, Slawomir J.
author_sort Terlikowska, Katarzyna M.
collection PubMed
description BACKGROUND: It is a well-known fact show that the risk of developing endometrial cancer (type 1 EC) is strongly associated with obesity. In this study, selected markers, such as obesity, insulin resistance, angiogenesis and inflammation markers related to EC type 1 progression and patients’ survival data were analyzed. METHODS: To measure levels of adiponectin, C-reactive protein (CRP), vascular endothelial growth factor-A (VEGF-A), angiopoietin-2 (Ang-2), insulin-like growth factor-1 (IGF-1), insulin and C-peptide in 176 preoperative serum samples, the immunoassay technique (EMIT) has been applied. RESULTS: Angiopoietin-2 levels increase with age (P = 0.005), FIGO stage (p = 0.042), myometrial invasion (P = 0.009) and LVSI (P < 0.001). The CRP levels increase with age (P = 0.01), as well as the advancement of the FIGO stage (P < 0.001), higher tumor grade (P = 0.012), and myometrial invasion (P < 0.001). A positive correlation between serum Ang-2 and CRP levels was demonstrated (r = 0.44; p < 0.001). Kaplan-Meier survival analysis showed that patients with high CRP levels in serum and Ang-2 presented a worse outcome (P = 0.03 and P = 0.015, respectively). Cox regression analysis of individual predictors revealed that high serum levels of Ang-2, CRP, advanced clinical FIGO stage (P < 0.001, respectively), old age (P = 0.013) were all significant overall survival predictors. By means of multivariate analysis, their predictive significance was confirmed. CONCLUSION: Our study provides evidence that serum levels of Ang-2 and CRP may serve as predictors for assessment of the clinical stage of type 1 EC and are significantly associated with poor prognosis. It is likely that angiogenesis and inflammation associated with obesity have a significant impact on EC type 1 progression and survival rate of patients.
format Online
Article
Text
id pubmed-7519537
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-75195372020-09-29 Clinical value of selected markers of angiogenesis, inflammation, insulin resistance and obesity in type 1 endometrial cancer Terlikowska, Katarzyna M. Dobrzycka, Bozena Terlikowski, Robert Sienkiewicz, Anna Kinalski, Maciej Terlikowski, Slawomir J. BMC Cancer Research Article BACKGROUND: It is a well-known fact show that the risk of developing endometrial cancer (type 1 EC) is strongly associated with obesity. In this study, selected markers, such as obesity, insulin resistance, angiogenesis and inflammation markers related to EC type 1 progression and patients’ survival data were analyzed. METHODS: To measure levels of adiponectin, C-reactive protein (CRP), vascular endothelial growth factor-A (VEGF-A), angiopoietin-2 (Ang-2), insulin-like growth factor-1 (IGF-1), insulin and C-peptide in 176 preoperative serum samples, the immunoassay technique (EMIT) has been applied. RESULTS: Angiopoietin-2 levels increase with age (P = 0.005), FIGO stage (p = 0.042), myometrial invasion (P = 0.009) and LVSI (P < 0.001). The CRP levels increase with age (P = 0.01), as well as the advancement of the FIGO stage (P < 0.001), higher tumor grade (P = 0.012), and myometrial invasion (P < 0.001). A positive correlation between serum Ang-2 and CRP levels was demonstrated (r = 0.44; p < 0.001). Kaplan-Meier survival analysis showed that patients with high CRP levels in serum and Ang-2 presented a worse outcome (P = 0.03 and P = 0.015, respectively). Cox regression analysis of individual predictors revealed that high serum levels of Ang-2, CRP, advanced clinical FIGO stage (P < 0.001, respectively), old age (P = 0.013) were all significant overall survival predictors. By means of multivariate analysis, their predictive significance was confirmed. CONCLUSION: Our study provides evidence that serum levels of Ang-2 and CRP may serve as predictors for assessment of the clinical stage of type 1 EC and are significantly associated with poor prognosis. It is likely that angiogenesis and inflammation associated with obesity have a significant impact on EC type 1 progression and survival rate of patients. BioMed Central 2020-09-25 /pmc/articles/PMC7519537/ /pubmed/32977765 http://dx.doi.org/10.1186/s12885-020-07415-x Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Terlikowska, Katarzyna M.
Dobrzycka, Bozena
Terlikowski, Robert
Sienkiewicz, Anna
Kinalski, Maciej
Terlikowski, Slawomir J.
Clinical value of selected markers of angiogenesis, inflammation, insulin resistance and obesity in type 1 endometrial cancer
title Clinical value of selected markers of angiogenesis, inflammation, insulin resistance and obesity in type 1 endometrial cancer
title_full Clinical value of selected markers of angiogenesis, inflammation, insulin resistance and obesity in type 1 endometrial cancer
title_fullStr Clinical value of selected markers of angiogenesis, inflammation, insulin resistance and obesity in type 1 endometrial cancer
title_full_unstemmed Clinical value of selected markers of angiogenesis, inflammation, insulin resistance and obesity in type 1 endometrial cancer
title_short Clinical value of selected markers of angiogenesis, inflammation, insulin resistance and obesity in type 1 endometrial cancer
title_sort clinical value of selected markers of angiogenesis, inflammation, insulin resistance and obesity in type 1 endometrial cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7519537/
https://www.ncbi.nlm.nih.gov/pubmed/32977765
http://dx.doi.org/10.1186/s12885-020-07415-x
work_keys_str_mv AT terlikowskakatarzynam clinicalvalueofselectedmarkersofangiogenesisinflammationinsulinresistanceandobesityintype1endometrialcancer
AT dobrzyckabozena clinicalvalueofselectedmarkersofangiogenesisinflammationinsulinresistanceandobesityintype1endometrialcancer
AT terlikowskirobert clinicalvalueofselectedmarkersofangiogenesisinflammationinsulinresistanceandobesityintype1endometrialcancer
AT sienkiewiczanna clinicalvalueofselectedmarkersofangiogenesisinflammationinsulinresistanceandobesityintype1endometrialcancer
AT kinalskimaciej clinicalvalueofselectedmarkersofangiogenesisinflammationinsulinresistanceandobesityintype1endometrialcancer
AT terlikowskislawomirj clinicalvalueofselectedmarkersofangiogenesisinflammationinsulinresistanceandobesityintype1endometrialcancer